+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

T-cell Acute Lymphoblastic Leukemia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987209
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Celegene Corporation
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab AS
  • GlaxoSmithKline
  • Kyowa Kirin Co., Ltd.
  • MORE
  • Major factor that is responsible for the growth of T-cell acute lymphoblastic leukaemia market is the rising prevalence of T-cell acute lymphoblastic leukaemia globally.
  • T-cell Acute Lymphoblastic Leukemia Treatment estimated for 15% to 20% of all acute lymphoblastic leukemia by study of the American Society of Clinical Oncology (ASCO). The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that, in 2019, there were around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females.
  • Additionally, growing research and development expenditure on cancer therapeutics, increasing healthcare expenditure and innovations in novel drug development are also propelling the growth of the T-cell acute lymphoblastic leukaemia market globally.
  • However, stringent regulations for the approval of T-ALL drugs, high cost of the treatment and adverse effects associated with therapies are the factors that may hamper the growth of the market.
Key Market Trends

Chemotherapy dominate the Global T-cell Acute Lymphoblastic Leukemia Treatment Market
  • The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy drugs are the cell-killing therapeutics. These drugs kill the cancer cells and stop them from dividing.
  • Chemotherapy is normally given as a combination of drugs and for T-ALL, will always include steroids. T-ALL cells is found in the cerebro spinal fluid (CSF) so chemotherapy for the T-ALL includes injections into CSF. This is called intrathecal chemotherapy. This is more common in T-ALL than in other forms of ALL.
North America Dominates the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

North America holds a significant market share in the global T-ALL Treatment market and is expected to withstand its position over the forecast period. The diagnosis and prevalence rates of T-ALL is growing rapidly in the region. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.

Competitive Landscape

Currently, many private companies are focusing on the development and introduction of novel therapeutics. Additionally, extensive research and development activities are being initiated by most of the market players, government organizations and academic research institutes. Some of the key innovations in the market are: In 2017, Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration in specific gene, known as Capicua, has been inactivated and that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celegene Corporation
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab AS
  • GlaxoSmithKline
  • Kyowa Kirin Co., Ltd.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of T-cell Acute Lymphoblastic Leukemia Market
4.2.2 Growing Research and Development Expenditure on Cancer Therapeutics
4.3 Market Restraints
4.3.1 Stringent Regulatory Scenario for the Drug Approvals
4.3.2 High Cost Asscoiated with the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Type of Therapy
5.1.1 Chemotherapy
5.1.2 Radiation therapy
5.1.3 Stem cell transplant
5.1.4 Others
5.2 By End User
5.2.1 Hospitals
5.2.2 Cancer and Radiation Therapy Centers
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 Bristol Myer Squibb Company
6.1.2 Celegene Corporation
6.1.3 Kyowa Kirin Co., Ltd.
6.1.4 Erytech Pharma
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genmab AS
6.1.7 GlaxoSmithKline
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Spectrum Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bristol Myer Squibb Company
  • Celegene Corporation
  • Kyowa Kirin Co., Ltd.
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab AS
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll